anti-myelin oligodendrocyte glycoprotein CAR Treg-cell therapy (Sangamo Therapeutics)

N/A

Report date: 2025/06/11 10:17:20

Base Information

Drug Nameanti-myelin oligodendrocyte glycoprotein CAR Treg-cell therapy (Sangamo Therapeutics)
Drug Alias NameMOG-CAR Tregs
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionRegulatory T-lymphocytes stimulantsMyelin-oligodendrocyte glycoprotein modulators
TargetsMyelin-oligodendrocyte glycoprotein
Therapy Area/IndicationsMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSangamo Therapeutics France Sas
China Registration ClassN/A

Develop Information

Active CompaniesSangamo Therapeutics France Sas
Inactive CompaniesN/A
Active IndicationsMultiple Sclerosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A